Advertisement

Journal of Neuro-Oncology

, Volume 137, Issue 1, pp 103–110 | Cite as

Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis

  • Cassie Kline
  • Erin Felton
  • I. Elaine Allen
  • Peggy Tahir
  • Sabine Mueller
Clinical Study

Abstract

Recurrent pediatric high-grade glioma is a leading cause of cancer-related death in children. We report results of a systematic review and meta-analysis investigating survival outcome in pediatric patients with recurrent high-grade glioma over the last 20 years. MEDLINE/PubMed, EMBASE, Web of Science and Cochrane Review databases were searched for relevant studies reporting on survival outcomes for pediatric patients with recurrent high-grade glioma treated between 1996 and 2016. Progression-free survival (PFS) and overall survival (OS) were calculated cumulatively over all studies, by therapy subgroup, and by decade of treatment. Random effects models were used to control for heterogeneity as measured by the I2 statistic. A total of 17 studies across 4 treatment strategies were included. Eleven investigated traditional chemotherapy, 1 investigated targeted therapy, 3 investigated immunotherapy, and 2 investigated radiotherapy. A total of 129 patients were included with a median age of 10.0 years. Cumulative PFS was 3.5 months (95% CI 2.1–5.0). Cumulative OS was 5.6 months (95% CI 3.9–7.3). OS was 4.0 months (95% CI 1.9–6.1) using traditional chemotherapy, 9.3 months using targeted therapies (95% CI 5.4–13), 6.9 months using immunotherapy (95% CI 2.1–12), and 14 months using reirradiation (95% CI 2.8–25). OS between 1996 and 2006 was 4.2 months (95% CI 2.1–6.2) compared to 8.5 months (95% CI 5.6–11) after 2006. Pediatric patients with recurrent high-grade glioma suffer from poor PFS and OS, regardless of therapy. There may be a trend towards improved OS in the last decade.

Keywords

Pediatric high-grade glioma Recurrence Survival Outcomes 

Notes

Acknowledgements

C.N.K. is supported by the National Institutes of Health T32 Grant (T32CA128583-07), UCSF Clinical and Translational Science Institute Strategic Opportunities Support Program (UL1 TR001872), Alex’s Lemonade Stand Foundation (A120729), and Frank A. Campini Foundation. S.M. is supported by the National Institutes of Health National Center for Advancing Translational Sciences through UCSF-CTSI (KL2TR000143). This work was presented as a podium presentation at the 4th Pediatric Neuro-Oncology Basic and Translational Research Conference in New York, NY on June 16, 2017 and as an eTalk at the Society of Neuro-Oncology Annual Meeting on November 17, 2017.

Funding

No external funding was used to directly support this study.

Compliance with ethical standards

Conflict of interest

No contributing authors have any conflict of interest to declare.

Supplementary material

11060_2017_2701_MOESM1_ESM.docx (106 kb)
Table of all studies included in final statistical analyses. Thio = thiotepa; BCNU = carmustine; O6-BG = O6-benzylguanine; TMZ = temozolomide; Chemo = varied chemotherapy; Topo = topotecan; Carbo = carboplatin; HD = high-dose; ASCR = autologous stem cell rescue; Etopo = etoposide; DC = dendritic cell. (DOCX 105 KB)
11060_2017_2701_MOESM2_ESM.tiff (1.5 mb)
Forest plot representing PFS by therapy (TIFF 1522 KB)
11060_2017_2701_MOESM3_ESM.tiff (1.5 mb)
Forest plot representing PFS by decade (TIFF 1522 KB)

References

  1. 1.
    Cage TA, Mueller S, Haas-Kogan D, Gupta N (2012) High-grade gliomas in children. Neurosurg Clin N Am 23:515–523.  https://doi.org/10.1016/j.nec.2012.04.007 CrossRefPubMedGoogle Scholar
  2. 2.
    Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. The Oncol 9:197–206Google Scholar
  3. 3.
    Gottardo NG, Gajjar A (2008) Chemotherapy for malignant brain tumors of childhood. J Child Neurol 23:1149–1159.  https://doi.org/10.1177/0883073808321765 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Braunstein S, Raleigh D, Bindra R, Mueller S, Haas-Kogan D (2017) Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neuro-Oncol.  https://doi.org/10.1007/s11060-017-2393-0 Google Scholar
  5. 5.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34.  https://doi.org/10.1016/j.jclinepi.2009.06.006 CrossRefPubMedGoogle Scholar
  6. 6.
    Mahoney DH Jr, Strother D, Camitta B, Bowen T, Ghim T, Pick T, Wall D, Yu L, Shuster JJ, Friedman H (1996) High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. J Clin Oncol 14:382–388.  https://doi.org/10.1200/JCO.1996.14.2.382 CrossRefPubMedGoogle Scholar
  7. 7.
    Chamberlain MC (1997) Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch Neurol 54:554–558CrossRefPubMedGoogle Scholar
  8. 8.
    Wagner S, Erdlenbruch B, Langler A, Gnekow A, Kuhl J, Albani M, Volpel S, Bucsky P, Emser A, Peters O, Wolff JE (2004) Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Cancer 100:1750–1757.  https://doi.org/10.1002/cncr.20168 CrossRefPubMedGoogle Scholar
  9. 9.
    Shih CS, Hale GA, Gronewold L, Tong X, Laningham FH, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M (2008) High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer 112:1345–1353.  https://doi.org/10.1002/cncr.23305 CrossRefPubMedGoogle Scholar
  10. 10.
    Saurez G, Cabanas R, Zaldivar M, Garnier T, Iglesias B, Piedra P, Castillo MR, Longchong M, Iznaga N, Lage A (2009) Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev 11:27–33PubMedGoogle Scholar
  11. 11.
    Parekh C, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J, Dhall G (2011) Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J Neuro-Oncol 103:673–680.  https://doi.org/10.1007/s11060-010-0444-x CrossRefGoogle Scholar
  12. 12.
    Lasky JL 3rd, Panosyan EH, Plant A, Davidson T, Yong WH, Prins RM, Liau LM, Moore TB (2013) Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 33:2047–2056PubMedPubMedCentralGoogle Scholar
  13. 13.
    Muller K, Scheithauer H, Pietschmann S, Hoffmann M, Rossler J, Graf N, Baumert BG, Christiansen H, Kortmann RD, Kramm CM, von Bueren AO (2014) Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group. Radiat Oncol 9:177.  https://doi.org/10.1186/1748-717X-9-177 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S, Wolff JEA, Van Gool SW (2010) Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 54:519–525.  https://doi.org/10.1002/pbc.22319 PubMedGoogle Scholar
  15. 15.
    Bouffet E, Khelfaoui F, Philip I, Biron P, Brunat-Mentigny M, Philip T (1997) High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol 39:376–379.  https://doi.org/10.1007/s002800050586 CrossRefPubMedGoogle Scholar
  16. 16.
    Bouffet E, Mottolese C, Jouvet A, Philip I, Frappaz D, Carrie C, Brunat-Mentigny M (1997) Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas. Eur J Cancer 33:91–95CrossRefPubMedGoogle Scholar
  17. 17.
    De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A (2006) Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer 47:30–36.  https://doi.org/10.1002/pbc.20516 CrossRefPubMedGoogle Scholar
  18. 18.
    Gilheeney SW, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel IJ (2010) Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatr Blood Cancer 54:591–595.  https://doi.org/10.1002/pbc.22347 PubMedGoogle Scholar
  19. 19.
    Gilman AL, Jacobsen C, Bunin N, Levine J, Goldman F, Bendel A, Joyce M, Anderson P, Rozans M, Wall DA, Macdonald TJ, Simon S, Kadota RP (2011) Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a pediatric blood and marrow transplant consortium study. Pediatr Blood Cancer 57:506–513.  https://doi.org/10.1002/pbc.22899 CrossRefPubMedGoogle Scholar
  20. 20.
    Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, Sato Y, Yoshida J, Suzuki S, Nishikawa H, Shiku H, Natsume A, Wakabayashi T (2012) Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy 14:733–742.  https://doi.org/10.3109/14653249.2012.666633 CrossRefPubMedGoogle Scholar
  21. 21.
    Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson ADJ, Vassal G, Frappaz D (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20:4684–4691.  https://doi.org/10.1200/JCO.2002.08.141 CrossRefPubMedGoogle Scholar
  22. 22.
    Papadakis V, Dunkel IJ, Cramer LD, Kramer E, Papadopoulos E, Goldman S, Packer RJ, Willoughby M, Baker D, Garvin J, Strandjord S, Coccia P, Kaplan AM, Klemperer M, Finlay JL (2000) High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors. Bone Marrow Transplant 26:153–160CrossRefPubMedGoogle Scholar
  23. 23.
    Verschuur AC, Grill J, Lelouch-Tubiana A, Couanet D, Kalifa C, Vassal G (2004) Temozolomide in paediatric high-grade glioma: a key for combination therapy? Br J cancer 91:425–429.  https://doi.org/10.1038/sj.bjc.6601997 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Jakacki RI, Cohen KJ, Buxton A, Krailo MD, Burger PC, Rosenblum MK, Brat DJ, Hamilton RL, Eckel SP, Zhou T, Lavey RS, Pollack IF (2016) Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children’s Oncology Group ACNS0423 study. Neuro Oncol 18:1442–1450.  https://doi.org/10.1093/neuonc/now038 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wolff JE, Wagner S, Reinert C, Gnekow A, Kortmann RD, Kuhl J, Van Gool SW (2006) Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neuro-Oncol 79:315–321.  https://doi.org/10.1007/s11060-006-9147-8 CrossRefGoogle Scholar
  26. 26.
    Wolff JE, Driever PH, Erdlenbruch B, Kortmann RD, Rutkowski S, Pietsch T, Parker C, Metz MW, Gnekow A, Kramm CM (2010) Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 116:705–712.  https://doi.org/10.1002/cncr.24730 CrossRefPubMedGoogle Scholar
  27. 27.
    Janssens GO, Gandola L, Bolle S, Mandeville H, Ramos-Albiac M, van Beek K, Benghiat H, Hoeben B, Morales La Madrid A, Kortmann RD, Hargrave D, Menten J, Pecori E, Biassoni V, von Bueren AO, van Vuurden DG, Massimino M, Sturm D, Peters M, Kramm CM (2017) Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer 73:38–47.  https://doi.org/10.1016/j.ejca.2016.12.007 CrossRefPubMedGoogle Scholar
  28. 28.
    Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, Veronesi U (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348–357CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of PediatricsUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.Department of NeurologyUniversity of California, San FranciscoSan FranciscoUSA
  3. 3.Department of Epidemiology & BiostatisticsUniversity of California, San FranciscoSan FranciscoUSA
  4. 4.UCSF LibraryUniversity of California, San FranciscoSan FranciscoUSA
  5. 5.Department of Neurological SurgeryUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations